Trial Profile

A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Aug 2018 According to a Cardiome Pharma media release, the China Food and Drug Administrations (CFDA) Center for Drug Evaluation (CDE) selected Brinavess as potentially eligible for priority review in China.Also, Brinavess was named one of 48 drugs deemed clinically urgent and targeted for expedited clearance based on existing ex-china clinical data which included positive results from this trial.
07 Nov 2014 Primary endpoint has been met (conversion to sinus rhythm, assessed within 90 minutes after first exposure), according to a Cardiome Pharma media release.
07 Nov 2014 Results published in a Cardiome Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com